General Atlantic LLC Akero Therapeutics, Inc. Call Options Transaction History
General Atlantic LLC
- $2.79 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
214Shares Held
67.4MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$313 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$275 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$255 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$197 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$169 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.12B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...